| Cash Flow | 2025-08-31 |
|---|---|
| Net (loss) income | -313,976 |
| Depreciation | 0 |
| Share based payment | 0 |
| Interest on convertible loan | -39,813 |
| Capital loss (gain) | 0 |
| Accounts receivable and prepaid expenses | -1,641 |
| Accounts payable and accrued liabilities | 101,217 |
| Net cash used in operating activities | -171,305 |
| Sale of equipment | 0 |
| Acquisition of equipment | 0 |
| Net cash used in investing activities | 0 |
| Proceeds from issuance of a convertible loan | 160,000 |
| Net cash provided by financing activities | 160,000 |
| Net increase (decrease) in cash | -11,305 |
| Cash and cash equivalents at beginning of period | 26,416 |
| Cash and cash equivalents at end of period | 15,111 |
CNBX Pharmaceuticals Inc. (CNBX)
CNBX Pharmaceuticals Inc. (CNBX)